EFEMP2 Mediates GALNT14-Dependent Breast Cancer Cell Invasion

Tao Zuo*, 1, Jinshuai Shan*, 1, Yang Liu*, Rong Xie*, Xiaochun Yu*,† and Chen Wu*

*College of Life Sciences, Hebei University, Baoding 071002, Hebei, P.R. China; †Department of Cancer Genetics and Epigenetics, Beckman Research Institute, City of Hope, 1500 E. Duarte Rd, Duarte, California, 91010, USA

Abstract
N-Acetylgalactosaminyltransferase-14 (GALNT14) is a member of acetylgalactosaminyltransferases family. We have shown that GALNT14 could promote breast cancer cell invasion. However, the underlying molecular mechanism is unclear. Here, using yeast two hybrid, we find that EGF-containing fibulin-like extracellular matrix protein 2 (EFEMP2) interacts with GALNT14. Both in vitro and in vivo binding assays show that EFEMP2 is associated with GALNT14. Moreover, we find that GALNT14 mediates glycosylation of EFEMP2. EFEMP2 significantly increased the invasion ability of breast cancer cells including MCF-7 and MBA-MD-231 cells, and this phenomenon is suppressed by knockdown expression of GALNT14. In addition, the GALNT14-dependent O-glycosylation of EFEMP-2 regulates the stability of EFEMP-2 protein in breast cancer cells. Taken together, our results demonstrate a novel molecular mechanism underlying breast cancer invasion.
[13]. However, the underlying mechanism of how these GALNTs are upregulated in human tumors is not fully understood.

Our previous studies have shown that GALNT14 is highly expressed in breast cancer and regulates malignant progression of breast cancer [14]. GALNT14 contributed to breast cancer invasion and migration by altering the cell proliferation, motility, and expression levels of epithelial-mesenchymal transition genes and stimulating MMP2 activity, suggesting that GALNT14 could be not only an important biomarker of breast cancer diagnostic but also a potential target for breast cancer treatment [15]. However, the underlying mechanism by which GALNT14 mediates breast cancer invasion remains elusive.

In this study, using yeast two-hybrid (Y2H), we found EFEMP2 as a novel partner of GALNT14. We demonstrate that GALNT14 mediates the O-glycosylation of EFEMP2, which facilitates breast cancer invasion.

Materials and Methods

Cell Culture

MCF-7 and MBA-MD-231 cell lines were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and maintained in Dulbecco’s modified Eagle’s medium ( Gibco, Carlsbad, CA) with 10% fetal bovine serum (GIBCO) and 1% penicillin/streptomycin at 37°C and 5% CO2 in a humidified incubator.

Plasmid Construction

The complete 1656-bp cDNA fragment of human GALNT14 (GenBank accession number: AB078144) was subcloned in frame into the EcoRI-SalI site of the DNA-Binding Domain (BD) vector pGBK7 (CLONTECH) to generate an expression plasmid pGBK7-GALNT14. The expression of bait GALNT14/GAL4 BD fusion protein was determined by Western blot of lysates from AH109 yeast cells transfected with this construct.

Yeast Two-Hybrid Screen

pGBK7-GALNT14 and pGADT7 were transfected into yeast AH109; cells were plated on SD-Leu-Trp medium and cultured at 30°C until colonies appeared. Then, colonies were plated on SD-Leu-Trp-His-Ade medium and cultured at 30°C for 2 to 3 days to test the autoactivation of the bait. The pGBK7-GANT14 bait vector and the human mammary gland Matchmaker cDNA library (CLONTECH, Cat. No. 638811) in the pACT2 vector were co-transfected into AH109 that were grown on SD-Leu-Trp-His-Ade medium at 30°C for 3 to 5 days to test potential interactions. Approximately 5×10⁶ independent transformants were pooled and replated on selection media (Ade-, His-, Leu- and Trp-) containing 2% galactose (Gal) to induce the expression of cDNAs. In total, four positive colonies were identified. Plasmids from these transformants were extracted, isolated, and sequenced. To eliminate false-positive results, candidate plasmids isolated from the primary screen were transfected into AH109 strain containing pGBK7-GALNT14 plasmid to assay the activation of reporter genes and reconfirm the positive candidates.

GST Pull-Down Assay

To reconfirm the interaction between GALNT14 and the cDNA clone identified by yeast two-hybrid system, GST pull-down assay with purified GST-GALNT14 fusion protein and His-EFEMP2 fusion protein was performed according to the method described in our previous work [16]. Briefly, the full-length cDNA of EFEMP2 was amplified from human 293T cDNA library. EFEMP2 and GALNT14 were subcloned into pET-28c and pGEX-4T-1 to construct pET-28c-EFEMP2 and pGEX-4T-1-GALNT14, respectively. The correct recombinant constructs were confirmed by sequencing. Expressions of EFEMP2 and GALNT14 were induced by IPTG. Target proteins were purified from the induced supernatants by using Glutathione-Sepharose 4B beads (GE Healthcare) and Ni-NTA agarose (GE Healthcare) according to the manufacturer’s instructions. Mix 1 μg GST-GALNT14 or GST protein with 1 μg His-EFEMP2 fusion protein, after incubation and washing, and the bound proteins were analyzed by 12% SDS-PAGE followed by Western blotting using anti-His antibody. The experiments were repeated three times.

Co-Immunoprecipitation

Co-immunoprecipitation (co-IP) analysis of EFEMP2 and GALNT14 followed the method that was described in detail [16]. Briefly, cells were harvested and lysed, and the protein contents were quantified using BCA protein quantitative kit (Sigma Aldrich). Fifty-microliter cell lysates were analyzed by Western blotting to quantify the expression level of the protein studied. EFEMP2 was precipitated by anti-EFEMP2 antibody (Santa Cruz), and using anti-GALNT14 antibody (Abcam) for Western blotting. The result was visualized by an enhanced chemiluminescence kit (Thermo Scientific).

Western Blot Analysis

For extraction of total protein, cells from two breast cancer cell lines, MCF7 and MBA-MD-231, were harvested and lysed in NP-40 lysis buffer. Extracted protein samples were measured by BCA protein assay (Pierce Chemical Co., Rockford, IL). Proteins were separated using SDS-PAGE and transferred onto nitrocellulose membrane for antibody detection. Antibodies against EFEMP2 and GAPDH were obtained from Santa Cruz (USA).

Lectin Blot

Total protein was extracted from MCF-7 or MBA-MD-231 cells or MCF-7 or MBA-MD-231 cells transfected with shRNA targeting GALNT14 (shRNA-T14) or control shRNA (shNC). EFEMP2 protein also was immunoprecipitated from MCF-7 or MBA-MD-231 cells and subjected to Vicia Villosa Lectin (VVL) blot. After being separated by 10% SDS-PAGE, proteins were transferred to NC membrane, and NC membrane was blocked in blocking solution (5% BSA in TBST). Membrane was incubated with a 0.2-μg/mL biotinylated VVL solution (B-1235, VECTOR Laboratories) and then membrane was incubated in secondary antibody: Streptavidin HRP conjugate (S911, Thermo Scientific). The result was visualized by an enhanced chemiluminescence kit (Thermo Scientific).

Cell Invasion Assay

The membrane inner surface of the Transwell chamber was coated with Matrigel, 1 × 10⁵ MCF-7 or MBA-MD-231 cells transfected with pCMV-Myc-EFEMP2 or pCMV-Myc empty plasmid, or co-transfected with shRNA-GALNT14 or shRNA-NC respectively. The cells were resuspended in 200 μl serum-free medium and added to the upper chamber, while 600 μl DMEM containing 20% fetal bovine serum was added to the lower chamber. After culturing for 24 hours, the cells were fixed with 4% paraformaldehyde in PBS buffer and
stained with 0.1% crystal violet to observe tumor cell infiltration across the membrane in order to determine the changes in the in vitro invasion of tumor cells. The migrated cells were photographed and counted at 200× magnification in 5 different fields per filter. The experiments were performed in triplicates.

**Statistical Analysis**

Data of cell invasion assay were analyzed using SPSS 19.0 software. P<0.05 was considered as statistically significant. All experiments were independently repeated at least 3 times.

**Results**

**Yeast Two-Hybrid Screening of GALNT14**

To identify novel partners of GALNT14, we performed yeast two-hybrid screening. Using a human mammary gland cDNA library, total of ~5×10^6 transfectants were screened. Four positive colonies were selected. The plasmids were extracted from these colonies, amplified in *E. coli*, and reintroduced into yeast cells to confirm the interaction. All of four colonies were shown to be positive clones. Subsequently, these positive clones were sequenced (Table 1). The strongest positive clone encodes partial EFEMP2 (161-443 a.a.), and we further characterized it.

**GALNT14 Interacts with EFEMP2 In Vitro and In Vivo**

To further confirm the direct interaction between GALNT14 and EFEMP2, we generated the recombinant GST-GALNT14 and His-EFEMP-2, incubated these two proteins together, and performed a GST pull-down assay. We have also included GST as a negative control and found that that His-EFEMP2 protein was bound to a GST pull-down assay. We have also included GST as a negative control. We further characterized it.

**GALNT14 Regulates the Stability of EFEMP2**

When the protein loading was normalized by GAPDH, we found that the protein level of EFEMP-2 was reduced when GALNT14 was knockdown, while O-glycosylation of EFEMP-2 was increased when GALNT14 was overexpressed (Figure 2B). Thus, the results indicate that GALNT14 mediates the O-glycosylation of EFEMP-2.

**GALNT14 Knockdown Reduces EFEMP-2–Induced Cell Invasion**

Protein O-glycosylation is associated with cancer cell invasion. To evaluate the biological function of GALNT14-dependent regulation of EFEMP2 in breast cancer cells invasion, we performed Matrigel-coated Transwell invasion assay in MCF-7 and MDA-MD-231 cells. Representative micrographs were taken from the lower surface of the Transwell filter, and the migrated cells were counted. As shown in Figure 4, cells with ectopic-expressing EFEMP2 exhibited a higher invasive ability than mock-transfected control cells, indicating that EFEMP2 mediates breast cancer cell invasion. Moreover, when we knocked down endogenous GALNT14 by shRNA, EFEMP2-mediated breast cancer cell invasion was clearly suppressed, suggesting that GALNT14 regulates EFEMP2-mediated breast cancer cell invasion.

**Discussion**

Tumor cells display a wide range of glycosylation alterations compared with their nontransformed counterparts. Protein glycosylation increases molecular heterogeneity as well as the functional diversity within cell populations. This heterogeneity occurs because abantant glycan modifications are protein specific, site specific (different sites on a given protein can be differentially glycosylated), and cell specific. In general, a shift from the normal glycosylation pathway occurs in cancer cells, leading to altered glycans expression due to under- or overexpression of glycosyltransferases (owing to dysregulation at the transcriptional level) [17,18].

In our previous work, we identified GALNT14 as a potential biomarker for breast cancer by immunohistochemistry [14]. We also found that GALNT14 played a critical role in cell migration, invasion, and proliferation of breast cancer by promoting the epithelial-mesenchymal transition of breast cancer cells. Since

| Positive Clones | Residues (a.a.) | β-gal Assay |
|-----------------|----------------|------------|
| 1. EFEMP-2      | 161-443        | +++        |
| 2. MT2A         | 1-61           | ++         |
| 3. ALDH2        | 346-517        | +          |
| 4. C1QC         | 27-245         | +          |
Figure 1. GALNT14 interacts with EFEMP2 both in vitro and in vivo. (A) GST pull-down assay demonstrating the binding between GALNT14 and EFEMP2 in vitro. GST-GALNT14 fusion protein (1.0 μg) was mixed with purified His-EFEMP2 (1.0 μg) and precipitated with glutathione-agarose followed by Western blot analysis. (B) GALNT14 co-IP with EFEMP2 in breast cancer cells MCF-7. Cell extracts were IPed with anti-EFEMP2 antibodies. Western blots were performed with indicating antibodies.

Figure 2. GALNT14 regulates the O-glycosylation of EFEMP-2. (A) The total O-glycosylation in GALNT14 knockdown (shRNA-GALNT14) MCF-7 and MBA-MD-231 cells was examined by VVL blotting. The cell lysate protein was stained using Coomassie blue. (B) The O-glycosylation of EFEMP-2 protein was examined in GALNT14 overexpression (FLAG-GALNT14) or knockdown (shRNA-GALNT14) MCF-7 and MBA-MD-231 cells by IP with anti-EFEMP2 and lectin blot.
overexpression of GALNT14 might contribute to mammary carcinogenesis, it would be valuable for development of novel therapeutic target against breast cancer [15]. Here, with unbiased approach, we found that GALNT14 mediated the O-glycosylation of EFEMP-2. EFEMP2 is a member of Fibulin family. Fibulin protein family is a family of glycoproteins consisting of a group of homologous proteins and facilitates cell motility[19,20]. Similar to other members in this family, EFEMP-2 facilitates breast cancer invasion. This activity is enhanced by GALNT14-dependent glycosylation. As the glycosylation stabilizes EFEMP-2, it prolongs the oncogenic functions in cancer cells. A previous study suggested that EFEMP-2 has two consensus sites for N-glycosylation, with Asn198 and Asn394, and a putative O-glycosylation site within the N-terminal end of human EFEMP-2 [16]. However, due to the limitation of the detection of O-glycosylation, we currently cannot map the O-glycosylation site. Future study may reveal the functional significance of each glycosylation event on EFEMP-2.

Conclusions

In summary, we find EFEMP2 as a novel partner of GALNT14. We demonstrate that GALNT14 mediates the O-glycosylation of EFEMP2, which facilitates breast cancer invasion. Thus, our study might reveal GALNT14 as a novel target for clinical treatment of breast cancer.

Acknowledgments

This work was supported by National Natural Science Foundation of China (grant numbers 31670812, 81672794); the grant for Returned Overseas Chinese Scholars of Hebei Province (grant number CY201602); and the Hundreds of outstanding talent innovation projects in Hebei Province (grant number SLRC2017023)

Author Contributions

Wu C. and Yu X. conceived and designed the study. Zuo T., Shan J. S., Liu Y., Xie R., Wang X., and Xiao B. H. performed the
experiments and collected the data. Liu Y., Liu C., and Wu C. C. analyzed the data. Zuo T., Yu X., and Wu C. wrote the manuscript. All authors read and accepted the final version of the manuscript submitted for publication.

Competing Interests
The authors declare that they have no competing interests.

Appendix A. Supplementary Data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.tranon.2018.01.021.

References
[1] Pegram MD, Borges VF, Ibrahim N, Fuloria J, Shapiro S, Perez S, Wang K, Schaedli Stark F, and Courtenay Luck N (2009). Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res 11, 73.
[2] Stowell SR, Ju T, and Cummings RD (2015). Protein glycosylation in cancer. Annu Rev Pathol 10, 473–510.
[3] Perrine CL, Ganguli A, Wu P, Bertozzi CR, Fritz TA, Raman J, Tabak LA, and Gerken TA (2009). Glycopeptide-prefering polypeptide GalNAc transferase 10 (ppGalNAc T10), involved in mucin-type O-glycosylation, has a unique GalNAc-O-Ser/Thr-binding site in its catalytic domain not found in ppGalNAc T1 or T2. J Biol Chem 284, 20387–20397.
[4] Ten Hagen KG, Fritz TA, and Tabak LA (2003). All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. Glycobiology 13, 1–16.
[5] Berois N, Mazal D, Uballos L, Trajtenberg F, Nicolas A, Sastre-Garau X, Magdelenat H, and Osinaga E (2006). UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 as a new immunohistochemical breast cancer marker. J Histochem Cytochem 54, 317–328.
[6] Gok F, Chefetz I, Indelman M, Kocaoglu M, and Sprecher E (2009). Newly discovered mutations in the GALNT3 gene causing autosomal recessive hyperostosis-hyperphosphatemia syndrome. Acta Orthop 80, 131–134.
[7] Olauson H, Krajinov T, Larsson C, Lindberg B, and Larsson TE (2008). A novel missense mutation in GALNT3 causing hyperostosis-hyperphosphatemia syndrome. Eur J Endocrinol 158, 929–934.

Figure 4. EFEMP-2 regulates breast cancer cell invasion via GALNT14. A total of 1 × 10^5 cells were plated onto the upper part of the Transwell chamber. After incubation for 24 hours, invasive cells were stained and counted at the lower part of transwell filter. (A) Photomicrographs obtained at 200×magnification. (B) Transmigration cells were counted for each of the indicated cells. The graph showed the mean and standard deviation of three separate experiments. *: P<0.05.
[8] Berois N, Blanc E, Ripoche H, Mergui X, Trajtenberg F, Cantais S, Barrois M, Dessen P, Kagedal B, and Benard J, et al (2006). ppGalNAc-T13: a new molecular marker of bone marrow involvement in neuroblastoma. *Clin Chem* **52**, 1701–1712.

[9] Wu YM, Liu CH, Hu RH, Huang MJ, Lee JJ, Chen CH, Huang J, Lai HS, Lee PH, and Hsu WM, et al (2011). Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor. *Cancer Res* **71**, 7270–7279.

[10] Wang H, Tachibana K, Zhang Y, Iwaski H, Kameyama A, Cheng L, Guo J, Hiruma T, Togayachi A, and Kudo T, et al (2003). Cloning and characterization of a novel UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase, pp-GalNAc-T14. *Biochem Biophys Res Commun* **300**, 738–744.

[11] Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, and Totpal K, et al (2007). Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. *Nat Med* **13**, 1070–1077.

[12] Sheta R, Bachvarova M, Plante M, Greigore J, Renaud MC, Sebastianelli A, Popa I, and Bachvarov D (2017). Altered expression of different GalNActransferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer. *Int J Oncol* **51**, 1887–1897.

[13] Liang KH, Yeh TS, Wu RC, Yeh CN, and Yeh CT (2017). GALNT14 genotype is associated with perineural invasion, lymph node metastasis and overall survival in resected cholangiocarcinoma. *Oncol Lett* **13**, 4215–4223.